Results 71 to 80 of about 2,874 (159)

Carbapenem‐Resistant Klebsiella pneumoniae Isolated From a Patient in a Midwestern U.S. Hospital With a History of Indian Travel: Therapeutic Strategies and Clinical Outcomes

Case Reports in Infectious Diseases, Volume 2025, Issue 1, 2025.
Carbapenemases have had increasing prevalence within the United States and worldwide. Here, we present a case of carbapenem‐resistant Klebsiella pneumoniae (CRKP) which is unique due to the rarity of multiple mechanisms of resistance within the Klebsiella pneumoniae harboring New Delhi metallo‐β‐lactamases (NDM), oxacillinase‐48 (OXA‐48)‐like, and ...
Christopher Phan, Kristen Tsai, Christian M. Gill, Robin Chamberland, Christian Hendrix, Rong Hou, Dawei Cui   +6 more
wiley   +1 more source

Simultaneous post-neurosurgical ventriculitis and bacteraemia by two different strains of KPC-producing K. pneumoniae successfully treated with meropenem/vaborbactam and high dose of fosfomycin

Journal of Global Antimicrobial Resistance
Objective: A case of post-neurosurgical ventriculitis caused by a KPC-producing Klebsiella pneumoniae (KPC-Kp) with a ceftazidime/avibactam-resistant, meropenem-susceptible phenotype is reported.
Lorenzo Volpicelli, Sara Cairoli, Dania Al Ismail, Floriana Baisi, Federica Sacco, Bianca Maria Goffredo, Mario Venditti, Alessandra Oliva   +7 more
doaj   +1 more source

Susceptibility evaluation of novel beta-lactam/beta-lactamase inhibitor combinations against carbapenem-resistant Klebsiella pneumoniae from bloodstream infections in hospitalized patients in Brazil

Journal of Global Antimicrobial Resistance
Introduction: Novel beta-lactam/beta-lactamase inhibitor (BIBLI) combinations are commercially available and have been used for treating carbapenem-resistant Klebsiella pneumoniae (CRKP) infections.
Camila Mörschbächer Wilhelm, Laura Czerkster Antochevis, Cibele Massotti Magagnin, Beatriz Arns, Tarsila Vieceli, Dariane Castro Pereira, Larissa Lutz, Ândrea Celestino de Souza, Jéssica Nesello dos Santos, Rafaela Ramalho Guerra, Gregory S. Medeiros, Lucas Santoro, Diego R. Falci, Maria Helena Rigatto, Afonso Luís Barth, Andreza Francisco Martins, Alexandre Prehn Zavascki   +16 more
doaj   +1 more source

National Cohort of Compassionate Use of Meropenem–Vaborbactam: No Benefit over Meropenem for Pseudomonas aeruginosa

Antibiotics
Background: Meropenem–vaborbactam (MEM-VAB) is a novel carbapenem-beta-lactamase-inhibitor combination that demonstrates activity against carbapenem-resistant (CR) Gram-negative bacteria, and more specifically KPC-producers, since vaborbactam is an ...
Aurélien Dinh, Alexandre Bleibtreu, Clara Duran, Frédérique Bouchand, Alexie Bosch, Jullien Crozon-Clauzel, Mariam Roncato-Saberan, Morgan Matt, André Boibieux, Annlyse Fanton, Heidi Wille, Elise Fiaux, Benoît Pilmis, Marie Lacoste, Quentin Saint-Genis, Caroline Thumerelle, Patricia Pavese, Fanny Vuotto, Eric Senneville, Anaïs Potron, Stéphane Corvec, David Boutoille, Katy Jeannot, Laurent Dortet, on behalf of the Meropenem-Vaborbactam French Study Group   +24 more
doaj   +1 more source

Antimicrobial susceptibility of enterobacterales causing bloodstream infection in United States medical centres: comparison of aztreonam-avibactam with beta-lactams active against carbapenem-resistant enterobacterales

BMC Infectious Diseases
Background Bloodstream infection (BSI) is associated with poor outcomes especially when effective antimicrobial therapy and control of infection source are delayed.
Helio S. Sader, John H. Kimbrough, Rodrigo E. Mendes, Mariana Castanheira   +3 more
doaj   +1 more source

In Vitro Activity of “Old” and “New” Antimicrobials against the Klebsiella pneumoniae Complex

Antibiotics
The Klebsiella pneumoniae complex is a commonly isolated bacteria in human infections. These opportunistic pathogens pose a serious threat to public health due to their potential transmission to the human population.
Alicja Sękowska
doaj   +1 more source

In Vitro Activities of Cefiderocol, Ceftazidime–Avibactam, Meropenem–Vaborbactam, Imipenem–Relebactam and Eravacycline Against Carbapenem-Resistant Klebsiella pneumoniae

Journal of Global Antimicrobial Resistance
AIM/BACKGROUND: Carbapenem-resistant Klebsiella pneumoniae (CRKP) infections are a significant global threat due to the limited treatment options. In this study, in vitro activities of novel antimicrobial agents were investigated against CRKP strains ...
FATMA SENA TÜRKDOĞAN, Betigul Ongen
doaj   +1 more source

Activity of Aztreonam-avibactam and other β-lactamase inhibitor combinations against Gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2020–2022)

BMC Pulmonary Medicine
Background Initial antimicrobial therapy for pneumonia is frequently empirical and resistance to antimicrobial agents represents a great challenge to the treatment of patients hospitalized with pneumonia.
Helio S. Sader, Rodrigo E. Mendes, S. J. Ryan Arends, Timothy B. Doyle, Mariana Castanheira   +4 more
doaj   +1 more source

Meropenem–Vaborbactam for the Treatment of Post-Neurosurgical Meningitis Caused by KPC Producer Klebsiella Pneumoniae: A Case Report and Review of the Literature

Antibiotics
Meningitis and ventriculitis, due to carbapenem-resistant Enterobacterales, are frequently associated with significant morbidity and mortality. In the case of multi-drug-resistant pathogens, it is necessary to consider the limited susceptibility profile ...
Leonardo Francesco Rezzonico, Francesco Peracchi, Marta Vecchi, Gabriele Bassi, Marco Merli, Nicholas Brian Bana, Giovanna Travi, Fulvio Crippa, Massimo Puoti   +8 more
doaj   +1 more source

Antimicrobial susceptibility of clinically important carbapenem-resistant Enterobacterales towards standard and new antibiotics

Journal of Global Antimicrobial Resistance
AIM: The aim of this work is to study carbapenem-resistant Enterobacterales (CRE) incidence, carbapenemase types and antimicrobial susceptibility of the strains to standard and new antibiotics.
Deniz Hamidov, Emma Keuleyan, Theodor Todorov, Radoslava Vazharova, Georgi Todorov, Atanas Syarov   +5 more
doaj   +1 more source